Medicinal Cannabis Europe

What Medicinal Cannabis Europe does

Cannabis Europe (legal name: Cannabis Europe; also referred to as Medicinal Cannabis Europe) is a Brussels-based, non-profit advocacy organization founded in 2018 that works to ensure patient access to high-quality, safe, cannabis-derived medicines across the European Union. Its stated mission is to harmonize the currently fragmented EU regulatory framework for medical cannabis, which the organization identifies as the principal barrier to consistent patient access. The organization is composed of four stakeholder groups: patient organizations, the medical and scientific communities, NGOs, and industry stakeholders, with member organizations drawn from countries including Germany, the Netherlands, the UK, and Belgium. It is not a commercial entity; rather, it functions as an industry/patient coalition coordinating EU-level public affairs.

The organization's core offerings are advocacy services, education and communication programs, member services, and event organization. It conducts and publicizes quantitative and qualitative research, produces position papers and value proposition documents, and disseminates regulatory updates through monthly newsletters. It organizes events at EU institutions — notably the European Parliament event on 11 April 2019 titled 'Ensuring fair access to medical cannabis for patients in Europe.' The Secretariat is managed by Hague Corporate Affairs, which provides administrative and operational support from Brussels. Member services include networking opportunities, regulatory and policy updates, and advisory on EU-funded project opportunities under Horizon Europe.

The business model is non-commercial: the organization does not sell products or services, has no disclosed revenue, no funding rounds, and no disclosed ownership structure. Operations are supported by a small team of approximately 6 employees and the outsourced secretariat. Distribution of the organization's work occurs through direct policy engagement with the European Commission, Members of the European Parliament, and national government officials; member communications via newsletters; and public-facing documents and events. A partnership with EnergyCasino (a gaming company) appears on the website as an outbound commercial arrangement but is unrelated to the medical cannabis advocacy mission.

Name

Medicinal Cannabis Europe

Legal name

Cannabis Europe

Website

https://cannabiseurope.org

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Medicinal Cannabis Europe (Cannabis Europe) is a Brussels-based non-profit advocacy coalition, founded in 2018, that brings together patient organizations, medical and scientific communities, NGOs, and industry to harmonize the fragmented EU regulatory framework and improve patient access to cannabis-derived medicines.

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels4 records

Core offering

Medicinal Cannabis Europe is a Brussels-based non-profit advocacy coalition that promotes the use of cannabis in medical applications to European policy-makers. It delivers public affairs and lobbying services, education and research dissemination on medical cannabis, and member services including networking events, regulatory updates via monthly newsletters, and advice on EU-funded project opportunities such as Horizon Europe. Its membership base spans patient organisations, medical and scientific communities, NGOs, and industry stakeholders across multiple EU countries.

Product overview

Cannabis Europe is an advocacy organization rather than a product company. The organization offers advocacy services to promote medical cannabis use to European policy-makers, education and communication services to inform stakeholders about medical cannabis applications, and member services including networking, regulatory updates, and EU funding advice. The organization also organizes events such as the European Parliament event in April 2019. No commercial products or technology platforms are offered.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Cannabis Advocacy Services Public affairs and lobbying service that promotes cannabis in medical applications and demonstrates patient benefits to European policy-makers; includes sustained dialogue with EU institutions and national government officials on behalf of members.
• Education and Communication Services
• Member Services
• Advocacy Events Convening of policy and stakeholder events, including European Parliament-level gatherings, to advance the medical cannabis policy agenda.

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor and core.

• EnergyCasinominorOthersCollaboration with EnergyCasino in the virtual gaming world. Described as an 'esteemed partner' providing gaming services.
• Hague Corporate AffairscoreImplementation/ SI/ Consulting PartnerManages Cannabis Europe's Secretariat, providing administrative and operational support for the organisation's activities in Brussels.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• European Industrial Hemp Association (EIHA): Industry association representing hemp producers and processors in the EU, advocating for harmonized regulation of cannabis-derived products; shares Cannabis Europe's EU policy-advocacy mandate across an adjacent plant-derived category.
• International Association for Cannabinoid Medicines (IACM): International scientific and medical association promoting research on cannabinoids and advocating for patient access to medical cannabis; directly comparable to Cannabis Europe in mission, membership structure, and policy-advocacy approach.
• Drug Science (UK): Independent scientific body providing evidence-based drug policy advice including on medical cannabis; comparable as a science-grounded advocacy organization working to reform drug/medicine regulation, primarily in the UK/Europe.
• Medical Cannabis Clinicians Society (UK): UK-based membership organization of clinicians advocating for medical cannabis access and education; shares Cannabis Europe's clinician-engagement and policy-reform focus but operates at a national rather than EU level.
• NORML (National Organization for the Reform of Marijuana Laws): Long-standing cannabis policy reform organization advocating for patient access and legal frameworks; functionally analogous to Cannabis Europe but US-rooted with international chapters, making it a mission peer rather than a direct geographic competitor.
• Americans for Safe Access (ASA): US national advocacy organization working to ensure safe and legal access to medical cannabis for patients; structurally analogous to Cannabis Europe as a multi-stakeholder coalition but operating in the US regulatory environment.

Broad incumbents

• European Patients' Forum (EPF): Cross-disease umbrella patient-advocacy organization in Brussels engaging EU institutions; comparable to Cannabis Europe in operating model (Brussels-based, EU policy advocacy, coalition of patient groups) but covers all therapy areas rather than medical cannabis specifically.
• European Federation of Pharmaceutical Industries and Associations (EFPIA): Large Brussels-based pharma industry association engaging EU regulators on medicines policy; comparable to Cannabis Europe in the industry-advocacy and EU-institutional access dimension but covering all pharmaceuticals rather than cannabis-derived medicines.
• European Public Health Alliance (EPHA): Brussels-based coalition of public-health NGOs engaging EU institutions on health policy; comparable in advocacy infrastructure and Brussels presence but with a far broader public-health remit than Cannabis Europe's cannabis-specific mandate.

Emerging players

• European Alliance for Access to Safe Medicines (EAASM): Brussels-based patient-safety focused alliance engaging EU institutions on medicines access and quality; shares Cannabis Europe's patient-access-to-medicines mission and Brussels operating footprint but with a broader (non-cannabis-specific) scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cannabis-europe

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicinal Cannabis Europe